Prostate Cancer International is
for 2011 by Great NonProfits
There are in fact three so-called “isozymes” (slightly different versions) of the human enzyme 5α-steroid reductase. The activity of 5α-reductase-II can be affected by the 5α-reductase inhibitor (5-ARI) finasteride (Proscar); the activity of 5α-reductase-I and -II can be affected by the 5-ARI dutasteride (Avodart), but
Filed under: Drugs in development, Prevention | Tagged: 5α-reductase, expression, inhibition | 1 Comment »
A recent review article concludes with the statement, “5α-reductase inhibition does seem to have beneficial effects on prostate cancer incidence, and the role of [5α-reductase inhibitors (5-ARIs)] in combination with other agents should be further evaluated for the treatment of [castration-resistant prostate cancer (CRPC)].”
Filed under: Drugs in development, Management, Treatment | Tagged: 5-ARI, 5α-reductase, abiraterone, inhibitor | 5 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site